<DOC>
	<DOCNO>NCT02885662</DOCNO>
	<brief_summary>To examine antihypertensive effect safety CS-3150 patient primary aldosteronism .</brief_summary>
	<brief_title>Study CS-3150 Patients With Primary Aldosteronism</brief_title>
	<detailed_description />
	<mesh_term>Hyperaldosteronism</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male female subject age 20 year old informed consent Patients diagnose primary aldosteronism screen test plasma aldosterone concentration PAC aldosterone renin ratio ( ARR ) , confirmatory test Patients satisfy follow blood pressure ; sit systolic blood pressure ( SBP ) ≥ 140 mmHg &lt; 180 mmHg sit diastolic blood pressure ( DBP ) ≥ 90 mmHg &lt; 110 mmHg Secondary hypertension except primary aldosteronism hypertensive emergency Patients diagnose diabetic nephropathy Patients type 1 diabetes eGFR &lt; 30 mL/min/1.73m2 Serum potassium level &lt; 3.0 ≥ 5.1 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Primary aldosteronism</keyword>
	<keyword>Hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>